Linezolid for Infants and Toddlers with Disseminated Tuberculosis: First Steps

Clinical Infectious Diseases

Volumn 63, Issue , 2016, Pages S80-S87

  Deshpande, Devyani ^a   Srivastava, Shashikant ^a   Pasipanodya, Jotam G ^a   Bush, Stephen J ^a   Nuermberger, Eric ^b   Swaminathan, Soumya ^c   Gumbo, Tawanda ^a,d  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

disseminated tuberculosis; hollow fiber model; pharmacokinetics pharmacodynamics; RNA sequencing; toxicity

Indexed keywords

LINEZOLID; MITOCHONDRIAL ENZYME; RIBOSOME PROTEIN; RNA; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CHILDHOOD DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; ENZYME INHIBITION; HOLLOW FIBER; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MACROPHAGE; MILIARY TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; PRIORITY JOURNAL; RNA SEQUENCE; AGE; CELL LINE; DRUG EFFECTS; DRUG MONITORING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; INFANT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; TUBERCULOSIS;

AGE FACTORS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CELL LINE; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIBOSOMAL PROTEINS; TUBERCULOSIS;

EID: 84994655873     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw482     Document Type: Article

References (33)

1. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367:1508-18.
2. Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb) 2014; 94:93-104.
3. Jungbluth GL,Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22:S153-7.
4. Datta M, Swaminathan S. Global aspects of tuberculosis in children. Paediatr Respir Rev 2001; 2:91-6.
5. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006; 10:732-8.
6. Starke JR. Pediatric tuberculosis: time for a new approach. Tuberculosis (Edinb) 2003; 83:208-12.
7. Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother 2010; 54:2534-9.
8. Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 2010; 54:1728-33.
9. Srivastava S, Pasipanodya JG, Ramachandran G, et al. A long-term co-perfused disseminated tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies. EBioMedicine 2016; 6:126-38.
10. De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42:1111-7.
11. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003; 348:86-7.
12. Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010; 32:66-88.
13. Garrabou G, Soriano A, Lopez S, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 2007; 51:962-7.
14. Garazzino S, Krzysztofiak A, Esposito S, et al. Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. J Antimicrob Chemother 2011; 66:2393-7.
15. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006; 50:2042-9.
16. Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 2015; 61(suppl 1):S18-24.
17. Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 2015; 61(suppl 1):S25-31.
18. Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 2015; 61(suppl 1):S10-7.
19. Døssing M, Vølund A, Poulsen HE. Optimal sampling times for minimum variance of clearance determination. Br J Clin Pharmacol 1983; 15:231-5.
20. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 2012; 56:5916-22.
21. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129-40.
22. Musuka S, Srivastava S, Siyambalapitiyage Dona CW, et al. Thioridazine pharmacokinetic-pharmacodynamic parameters "wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother 2013; 57:5870-7.
23. Swaminathan S, Pasipanodya J, Ramachandran G, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 2016; 63(suppl 3):S63-74.
24. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464-73.
25. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53:1314-9.
26. Brown AN, Drusano GL, Adams JR, et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio 2015; 6: e01741-15.
27. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55:24-34.
28. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 2015; 211(suppl 3): S96-106.
29. Srivastava S, Deshpande D, Manthati V, Sherman C, Cirrincione K, Gumbo T. Linezolid has excellent sterilizing effect against Mycobacterium tuberculosis (Mtb) at less toxic doses of monotherapy and combination therapy. In: Interscience Conference on Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy Meeting 2015, San Diego, CA, 17-21 September 2015.
30. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41:2132-6.
31. Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed Engl 2003; 42:2010-23.
32. Song T, Lee M, Jeon H-S, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine 2015; 2:1627-33.
33. Srivastava S, Deshpande D, Pasipanodya J, et al. Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks. Clin Infect Dis 2016; 63(suppl 3):S102-9.